Download MendeleyDiscovery of BAY-985, a Highly Selective TBK1/IKK epsilon Inhibitor.
Lefranc, J., Schulze, V.K., Hillig, R.C., Briem, H., Prinz, F., Mengel, A., Heinrich, T., Balint, J., Rengachari, S., Irlbacher, H., Stockigt, D., Bomer, U., Bader, B., Gradl, S.N., Nising, C.F., von Nussbaum, F., Mumberg, D., Panne, D., Wengner, A.M.(2020) J Med Chem 63: 601-612
- PubMed: 31859507
- DOI: https://doi.org/10.1021/acs.jmedchem.9b01460
- Primary Citation of Related Structures:
6RSR, 6RST, 6RSU - PubMed Abstract:
The serine/threonine kinase TBK1 (TANK-binding kinase 1) and its homologue IKKε are noncanonical members of the inhibitor of the nuclear factor κB (IκB) kinase family. These kinases play important roles in multiple cellular pathways and, in particular, in inflammation. Herein, we describe our investigations on a family of benzimidazoles and the identification of the potent and highly selective TBK1/IKKε inhibitor BAY-985. BAY-985 inhibits the cellular phosphorylation of interferon regulatory factor 3 and displays antiproliferative efficacy in the melanoma cell line SK-MEL-2 but showed only weak antitumor activity in the SK-MEL-2 human melanoma xenograft model.
Organizational Affiliation:
Pharmaceuticals, Research and Development , Bayer AG , 13353 Berlin , Germany.
